Monday, May 30, 2011

Cold Laser Therapy: Theory and Clinical Applications Seminar http://ping.fm/9yPZr

Cold Laser Therapy: Theory and Clinical Applications Seminar

Cold Laser Therapy: Theory and Clinical Applications

Presented by Canadian Memorial Chiropractic College Division of Continuing Education and TheraLase Technologies Inc 
Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)

Location: 
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
  • Understand how laser light affects tissues and healing
  • Identify musculoskeletal injury types that are indicated for primary or adjunctive laser treatment
  • Design clinical laser treatment programs, including frequency of treatments, duration of care, and targeting for musculoskeletal injuries
  • Select optimal laser dosage, including power and time settings, to treat a variety of musculoskeletal conditions in a clinical setting.
  • Operate a laser safely, including treatment room design and patient and technician procedures
  • Differentiate laser equipment through the comparison of key technology parameters

Friday, May 20, 2011

Dr. James Andrews has Treated Over 60 Hall of Famers & All Stars with the Theralase http://ping.fm/QNVSH

Dr. James Andrews has Treated Over 60 Hall of Famers & All Stars with the Theralase

Dr. James Andrews sits on Theralase's Medical Advisory Board and has used Theralase's Super Pulsed laser technology for a number of years on many professional athletes. For more information, please click on the link.   http://bit.ly/kMktHY 

Thursday, May 19, 2011

The Healing of Chronic Wounds by Laser Therapy http://ping.fm/tUtxM

The Healing of Chronic Wounds by Laser Therapy

In addition to accelerated wound healing, the main advantages of LLLT for postoperative sport‐and traffic‐related injuries include prevention of side effects of drugs, significantly accelerated functional recovery, earlier return to work, training and sport competition compared to the control group of patients, and cost benefit.
http://bit.ly/k1sf8U 

Wednesday, May 18, 2011

See What Equine Vets are Saying About Theralase http://ping.fm/0HfM0

See What Equine Vets are Saying About Theralase

Muscle, tendon and wounds are common in equine athletes. These tissues are highly vulnerable to
repetitive stress and can be career ending if not treated properly the first time. Veterinarians across North
America have discovered a modern treatment tool that heals injuries on a cellular level using the Theralase line
of therapeutic laser products.
The Theralase superpulsed laser system can deeply penetrate through the hair and skin of an equine athlete
promoting cellular regeneration at the source of the injury. Laser light energy helps to repair damaged cells by
accelerating the body’s natural healing mechanisms. Depending on the severity of the injury, your patient can
return to competition within a few weeks versus a few months of stall rest.
http://bit.ly/lgm5X0 

Tuesday, May 17, 2011

Theralase Quarterly Newsletter

May 2011
Theralase Quarterly Newsletter
An update for clients, investors and employees

New Territory Sales Managers Hired
As previously announced we have segmented the Canadian and US markets and hired 7 new Territory Sales Managers. We can utilise dedicated sales personnel to meet increasing demand and better service our existing clients. We are confident our new strategy will help Theralase expand into the larger US market and significantly increase the sale of our medical lasers in 2011 and beyond.
·         Lance Arianna will head up the US South Central territory. Based out of Dallas, Texas, Mr. Arianna brings over 20 years of medical sales experience to the table selling medical lasers, capital medical equipment and pharmaceuticals.
·         Gary Kazimer will head up the Western Canada territory. Based out of Calgary, Alberta, Mr. Kazimer has over 22 years of medical sales experience in the area of medical diagnostic equipment and has sold lasers into both the ophthalmic and aesthetic medical markets in Western Canada.
·         Marino Ricci will head up the Eastern Canada territory. Based in Ottawa, Ontario, Mr. Ricci is fully bilingual and has been selling medical devices, lasers and aesthetic products into the Quebec and Maritimes market for more than 8 years.
·         James Vaughn will head up the US North East territory. Based out of Long Island, New York, Mr. Vaughn has over 13 years of medical sales experience and over 10 years selling capital medical equipment, including medical lasers, into New York area hospitals and private medical practices.
·         Brad Green will be covering the Southeast portion of the United States. He has over 20 years of experience in the medical device industry with 7 years as a process and product development engineer, and 14 years as a sales professional which includes 5 years in a managerial role. He has represented a variety of different products sold to hospitals, physician offices, veterinary facilities and acute/secondary care centers.
·         Kim Hillman will be covering the Western US Region for Theralase.  With over 2 years direct experience in laser sales and over 8 years of experience in the pharmaceutical industry, Kim has developed key relationships with thought leaders in the medical community across the Western region.  Including the last 10 years in the Medical Industry, Kim has a total of 25 years in Sales & Marketing.
·         Derek McDonald will be covering the Ontario region in Canada. He has over 23 years in professional sales, with 13 years in surgical and medical laser sales.

To support the marketing efforts of our Territory Sales Managers, Jules Gervais has been appointed as an Inside Sales Representative. Jules brings 9 years of professional sales experience to Theralase.
The addition of these new experienced professional sales representatives and our recently announced focused marketing program, combined with the improving economies in the United States and Canada, Theralase is well positioned for future growth.

Chief Scientific Officer Appointed
Dr. Arkady Mandel M.D., Ph.D., DSc. is not only an esteemed medical professional and an internationally respected scientist, but also an experienced executive manager of research and development teams dedicated to the field of biotechnology and drug development. We look forward to working with Dr. Mandel to lead the research and development of our core technologies through to commercialization; specifically, our patented photo dynamic technology platform for the treatment of cancer and eradication of bacteria and viruses, as well as our patented super-pulsed biofeedback laser technology used for the treatment of inflammation and pain in numerous medical conditions.

General Manager Appointed for Its Therapeutic Division
Mr. Jorge Cordoba BEng., M.Sc. MBA has over 16 years of experience in leading numerous high technology manufacturing companies to success, providing general management expertise in local and international sales, marketing, production, operations and regulatory affairs. As General Manager of its Therapeutic Division, Mr. Cordoba will be able to help take Theralase’s patented intellectual property to the next level and dramatically increase its revenue over the next few years.


Sporting Life 10K Run
On May 1st, 2011 Theralase participated in the Sporting Life’s 10K run in Toronto, for Kids with Cancer in support of Camp Oochigeas.
The event was a great success, drawing over 15,000 runners. Each participant was given a promotional card entitling them to one free laser treatment at a participating Theralase clinic. Theralase also was able to treat quite a few athletes at our own tent set up at the finish line of the race. I am also pleased to inform you that the event also surpassed our expectations in terms of the amount of people we were able to treat onsite after the race.
During these treatments on Sunday, several people commented on the immediate therapeutic benefits of the Theralase laser treatment, reporting significant improvements in their various conditions such as knee, lower back, and ankle pain. Not only do these testimonials help confirm the efficacy of our technology, they also help to promote and build awareness for our brand and our therapeutic offerings.
Given our ongoing research with Princess Margaret Hospital, and our interest in giving back to our local community, Theralase will be sponsoring additional runs, walks and races in the Greater Toronto Area in 2011. All of these events are in support of the fight against cancer.
In the last few days, several people have called us to schedule their free treatment. I expect that other participating clinics will receive similar requests. To our participating chiropractic clients, physiotherapists and medical practitioners, we would appreciate hearing from you about this initial sponsorship program, the patient response, and any other ideas you might have. Your input will help us to better plan and execute these programs in the future.

Centers of Excellence
Our first Centers of Excellence program will be taking place May 18th at the Chiropractic Center of Lakeland in Florida. Dr. Stephen Johnson and Brad Green will be facilitating the event.
The objective of the Centres of Excellence program will be to educate chiropractors in an informal format about the benefits of the Theralase laser technology and how it will help grow their practice.
There are 4 more Centres of Excellence programs scheduled over the next 6 weeks throughout North America.



Equine Sales Team Launch
The Company launched a laser sales team dedicated to the sale of the Company’s products to the equine industry. The Theralase equine sales team supplies therapeutic medical laser technology to veterinarians, horse owners and trainers. Theralase lasers are able to reduce pain and inflammation, while stimulating the growth of new tissue, substantially speeding the return of their equine athletes to top performance.
To accomplish this, Theralase has added an experienced sales team to service the horse industry, including Doug Nash and David Groves. Mr. Nash has over 30 years of hands-on experience in the standard bred industry and is an instructor teaching courses through Equine Guelph and the REACH campus at the University of Guelph. Mr. Groves, President, Equine World Sales Division has been with Theralase for 5 years and has over 20 years experience in the North American healthcare market successfully launching healthcare products.
The Company is delighted to have two seasoned professionals, Doug and David, to head up our equine sales efforts. All members bring decades of hands-on experience to the table, which will ultimately benefit the Company in both expanded knowledge of the horse industry and increased revenue.
The sales team is supported by Dr.Terry Ruch DVM, and a member of Theralase’s Medical Advisory Team. Dr. Ruch is a graduate of the University of Guelph (1974) and has devoted his practice to equine medicine – focusing on the diagnostic and orthopaedic examination of equine athletes. He has been deeply involved with equine sports medicine for the past 37 years and is highly regarded in his field.

Research Updates
Theralase Achieves Success in Destruction of Listeria Bacteria
As previously announced Theralase has developed a new application for its Photo Dynamic Compounds (PDC's); specifically, the destruction of Listeria Monocytogenes, a widely prevalent disease causing bacteria.
The patented Theralase PDCs have shown an ability to destroy bacteria in vitro when light activated, in new research performed at the renowned Princess Margaret Hospital, University Health Network (UHN). Future applications of the PDC technology in bacteria destruction may involve: food safety through food processing equipment sterilization, hospital treatment room sterilization, medical equipment sterilization, bacterial load elimination in wounds and other bacteria destruction applications.
Dr. Lothar Lilge, a scientist at the Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network adds, "Our initial research has demonstrated that the PDC destruction of bacteria is possible. Under further research and development these PDCs represent an opportunity in the area of bacterial destruction for food safety and hospital sterilization."
Theralase Cancer Therapy Trials Prove Safety of Patented Compounds
As previously announced Theralase has successfully completed the pre-clinical safety testing in an in vivo mouse model, the next step in the commercialization of its innovative Photo Dynamic Compound (PDC) platform technology. The Theralase patented PDC's comprise a family of novel drug candidates under evaluation from the company's proprietary PDC inventory focused on oncological indications.
Lothar Lilge Ph.D., the principal investigator of the Theralase PDC cancer compound technology at the Ontario Cancer Institute of the renowned Princess Margaret Hospital, University Health Network stated that, "For the four lead PDCs under investigation the Mean Tolerated Dose (MTD) was determined in an established in-vivo pre-clinical safety model and was well tolerated by animals at levels comparable to and above that of other FDA approved photosensitizers. Results demonstrate that the observed MTD was ten times higher than clinical doses of photosensitizers currently employed in medical practice. This provides the basis of a strong safety and tolerability profile of the patented Theralase PDCs. It also provides the required data to allow our research to proceed to the next stage; specifically, the determination of the effectiveness of the Theralase PDCs in the selective destruction of cancerous tumours growth and metastatic spread, while preserving normal tissue. We will also evaluate skin photosensitivity and the tissue selectivity of the PDCs to cancer versus normal tissue structures during treatment. I am encouraged by the results achieved to date and my team looks forward to establishing the efficacy of the Theralase PDCs in these established cancer models, as our research progresses."

A New Focus at Theralase
These are exciting times at Theralase. The many developments in research and product development will create a significant opportunity for the Company. The marketplace has adopted our patented, super-pulsed laser technology as the industry standard. Our technology is proved to be safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care.
The addition of experienced medical sales professionals, a focused marketing plan, an improving US economy and the public’s desire for high efficacy, drug-free treatments in an aging population places us in an enviable position for future growth. In addition, an exciting new Theralase Website will be launched in the next few weeks.



About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications in the United States, Canada and internationally. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. These applications extend to the care of animals by veterinarians. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.
Theralase Technologies Inc. trades on the Toronto Stock Venture Exchange under the trading symbol TLT.
For sales information, please contact Kristina Hachey at 1-866-843-5273
For investor information, please contact Greg Bewsh at 1-866-843-5273

This Quarterly Newsletter may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

Thursday, May 12, 2011

The Benefits of Laser Therapy http://ping.fm/Ms7PS

The Benefits of Laser Therapy

  • Non-Toxic
  • Non-Invasive
  • Easy to Apply
  • No Side Effects or Pain
  • Extremely Safe
  • Cost Effective for Practitioner and Patient
  • Highly Effective for Patient (>90% efficacy)
  • Growing Acceptance of Laser Technology
  • Superior Alternative to: Analgesics, NSAID’s, Other Medications, Other Modalities
  • Reduces Need for Surgery
  • Virtually No Contra-Indications
Therapeutic Laser Biological Effects
Rapid Cell Growth – Laser light accelerates cellular reproduction and growth.
Faster Wound Healing – Laser light stimulates fibroblast development and accelerates collagen synthesis in damaged tissue.
Increased Metabolic Activity – Higher outputs of specific enzymes, greater oxygen and food particle loads for blood cells and thus greater production of the basic food source for cells, Adenosine Tri-Phosphate (ATP).
Reduced Fibrous Tissue Formation – Laser light reduces the formation of scar tissue following tissue damage from: cuts, scratches, burns or post surgery.
Anti-Inflammatory Action – Laser light reduces swelling caused by bruising or inflammation of joints to give enhanced joint mobility.
Increased Vascular Activity – Laser light induces temporary vasodilation increasing blood flow to damaged areas.
Stimulated Nerve Function – Slow recovery of nerve function in damaged tissue can result in “dead” limbs or numb areas. Laser light speeds the process of nerve cell reconnection to bring the numb areas back to life.


Theralase Technologies Inc.  www.theralase.com   1-866-TheLase(843-5273)

Tuesday, May 10, 2011

See What Horse Owners are Saying About Theralase Laser Therapy http://ping.fm/d7WAj

See What Horse Owners are Saying About Theralase Laser Therapy

Theralase designs, develops and manufactures patented, super-pulsed laser technology utilized in biostimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions, and wound care for human, equine, and companion animals.

Muscle, tendon and wounds are common in equine athletes. These tissues are highly vulnerable to repetitive stress and can be career ending if not treated properly the first time. Veterinarians across North America have discovered a modern treatment tool that heals injuries on a cellular level using the Theralase line of therapeutic laser products.
The Theralase superpulsed laser system can deeply penetrate through the hair and skin of an equine athlete promoting cellular regeneration at the source of the injury. Laser light energy helps to repair damaged cells by accelerating the body’s natural healing mechanisms. Depending on the severity of the injury, your patient can return to competition within a few weeks versus a few months of stall rest.
http://www.theralase.com/www/documents/web_equine_booklet_2011.pdf 

Monday, May 9, 2011

6 Reasons to Incorporate Low Level Laser Therapy into your Practice

  • Numerous treatment capabilities from Low Level Laser Therapy (LLLT) include treatment of: arthritis, tendon and ligament problems, nerve root irritation, neck, shoulder and back pain, repetitive stress injuries, TMJ, plantar fascitis, burns, wounds, acne, skin conditions, acupuncture and trigger points, addiction treatments & more. LLLT causes certain photochemical reactions to occur to help control pain, reduce inflammation, and accelerate healing of damaged tissue.
  • Fast, efficient and painless treatment: Low level laser therapy is painless and gives great clinical results with a minimum time involvement. Low level laser therapy will increase your patient compliance and satisfaction through efficient and highly effective treatment.
  • You will grow your practice by providing additional proven pain management, injury and wound care rehabilitation to your existing patient base. Many patients have claimed that the laser is what made the difference in accelerating their healing and getting them well. You will find that many returning patients specifically request to have laser therapy.
  • You will attract new patients, which will seek your care due to the need for therapeutic laser rehabilitation treatments. Referrals will come in from medical doctors, healthcare practitioners and coaches who know you use low-level laser therapy.
  • Set your clinic apart from the competition by providing the most modern form of therapeutic technology.
  • Increase profitability of your practice though more treatment options & additional billable services.
Theralase Technologies Inc. (TSXV : TLT) designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, (including arthritis) secondly, to bio-stimulate and accelerate wound care and healing, (including; bone fracture regeneration and osteoarthritic conditions) and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacterium, viruses and fat cells.
Contact us at 1-866-843-5273 www.theralase.com 

Friday, May 6, 2011

Survey of Profession Finds That Laser Care Increases Revenues http://ping.fm/iId1E

Survey of Profession Finds That Laser Care Increases Revenues

An impressive 92% of DCs who use laser care would recommend other DCs add therapeutic lasers to their practice, a Dynamic Chiropractic email survey has found. Not surprisingly perhaps, 75% of those who would recommend it to peers said it is because these devices have proven to be a very effective part of their treatment strategy, while 45% said their patients enjoy laser care and have referred others as a result of the laser care.
As Dr. Todd Austin of Illinois remarked: "Our clinic's low level lasers improve ROM, decrease inflammation and edema, help to increase oxygenation of the damages target issues, speed up the healing process and (even more importantly in my opinion) increase the damaged tissue's ability to handle additional stress. The bottom line is: if there are damaged cells or tissues present, LLLT (low-level laser therapy) will usually be of benefit."
Equally impressive are the business results our respondents reported: Forty percent said they have seen an increase in practice income as a result of incorporating laser therapy into their treatments. Another 26% reported that the reputation of their practice has improved.
Who Uses Lasers and How
Approximately a third of DCs utilize laser care on half or more of their patients. When asked about the patient complaints they had the most success addressing with laser care treatment, they responded:
  • Extremity Pain - 77%
  • Neck & Shoulder Pain - 72%
  • Back Pain - 60%
  • TMJ Disorders - 41%
  • Disc Herniation - 29%
  • Disc Herniation with Radiculopathy - 27%
Laser care fits well into the chiropractic philosophy with 94% of DC users totally or somewhat agreeing that they "believe in the philosophy of laser care."
One doctor who took the survey noted: "Overall, I find it a very effective therapy when used alone and works excellently with Chiropractic adjustments." Stephen Fedele, Jr., DC, of California agrees: "It speeds recovery and shows that they can recover without drugs and surgery."
Quality is not an issue as 90% totally or somewhat agreed that they are "confident in the quality of my laser." And while price can always be a challenge, just under 60% agreed (totally or somewhat) that their laser was "very affordable." Dr. Stephen M. Savoie of Florida said laser therapy "is an extremely effective modality that provides pain relief and recovery with less effort on the doctor's part at an affordable price."
Why Not Use Lasers?
So why don't more doctors of chiropractic use lasers in their practice? The answer appears may be a lack of information.
Only 45% of DC users totally agreed that they were ready to use their laser based upon the "information provided with my laser." Many DCs gained additional information before and after they made their purchase from a number of sources (see accompanying graphic).
This same theme is echoed by doctors who don't current own lasers, but are considering making a purchase. Less than half are "very" or "somewhat" confident in their "understanding of lasers and their application in your practice."
When asked what additional information would assist them in making their decision, doctors who considering purchasing a laser device for their practice stated overwhelmingly preferred they wanted in writing or from attending seminars and webinars.
Laser Preferences
One of the more interesting data points to emerge from this survey was the apparent lack of differentiation between "high level" lasers (Class IV/above 500 milliwatts) and "low level" lasers (Class III/below 500 milliwatts). When asked which type of laser these doctors are considering to purchase, 54% stated "either." This may also suggest that doctors believe that both are equally effective.
Lasers are clearly seen as a valuable clinical tool by those DCs who are currently using them in their practice. They are seen as an effective adjunct to the adjustment, fitting both philosophically and financially. In addition they increase both income and referrals for almost half of the DCs who use them. According to William J. Kneebone, DC, of California "Therapeutic laser provides the most rapid and predictable relief of any modality that I've used in my 32 years of practice.
Those doctors thinking about adding lasers to their care should spend a good amount of time learning about how lasers work and what specific products are available. DCs will want to be confident that they are purchasing the right therapeutic laser for their practice.

Wednesday, May 4, 2011

Toronto Blue Jays Use Theralase Laser Technology http://www.theralase.com/brochures/Blue%20Jays%20ad%20(Apr%20-%20June).pdf

Toronto Blue Jays Use Theralase Laser Technology

"The Toronto Blue Jays use Theralase Theralase is without a doubt, the most effective therapeutic laser technology we have ever used. Our players love it, our team loves it". said Toronto Blue Jays Head Trainer George Poulis. check out http://bit.ly/m9Fdnx

Tuesday, May 3, 2011

Cold Laser Therapy: Theory and Clinical Applications Seminar

Presented by Canadian Memorial Chiropractic College Division of Continuing Education and TheraLase Technologies Inc 

Credit Hours: 6
Speakers:
Michael Bilas, BSc P.T.
Martin Lapointe, DC
Date & Time:
Saturday, June 4, 2011 (9:00 a.m. - 4:00 p.m.)

Location: 
Le Nouvel Hotel & Spa
1740 boul. René-Lévesque Ouest
Montréal, QC
This one day lecture and hands on workshop will focus on the use of laser therapy in a clinical practice. It will also provide participants the material and theories on how lasers work, the effects of laser on living tissue, and the use of lasers in treating specific neuromuscular conditions.
Program Objectives
  • Understand how laser light affects tissues and healing
  • Identify musculoskeletal injury types that are indicated for primary or adjunctive laser treatment
  • Design clinical laser treatment programs, including frequency of treatments, duration of care, and targeting for musculoskeletal injuries
  • Select optimal laser dosage, including power and time settings, to treat a variety of musculoskeletal conditions in a clinical setting.
  • Operate a laser safely, including treatment room design and patient and technician procedures
  • Differentiate laser equipment through the comparison of key technology parameters
Theralase Technologies Inc. Announces its Year End Financial Results http://ping.fm/3zQcM

Theralase Technologies Inc. Announces its Year End Financial Results

Company Primed for Growth - Exciting Progress in Research and Development

Toronto, Ontario – May 2, 2011 (Marketwire Canada) Theralase Technologies Inc. (TSX‐V: TLT) announces its year end 2010 financial results.

Total revenue for twelve months ending December 31, 2010 at $2,040,537 compared to $2,359,855 for the same period in 2009.

Selling expenses increased by 39%, to $662,064 for the twelve month period ending December 31, 2010 compared to $476,416 for the same period in 2009. The percentage increase is due to increased spending on travel and advertising. 

A 26% increase in administrative expenses ($1,255,572 for twelve months ending December 31, 2010 compared to $992,742 for the same period in 2009) represents increased expenditures on stock‐based compensations and salaries (recent hires – sales, production and accounting).

Roger Dumoulin‐White, President and CEO of Theralase Technologies Inc. stated, “The net loss for the period ended December, 2010 was $1,199,725, which included $303,610 of non‐cash expenses (amortization, stock‐based compensation expense, and foreign exchange gain/loss and lease inducements). Research and development expenses increased by 334% from $164,184 in 2009 to $547,987 in 2010. The company expenses the future product development costs of the TLC‐2000 Biofeedback Therapeutic Laser and TLC‐3000 Photo Dynamic Compound Cancer Destruction Technology from existing TLC‐1000 therapeutic laser product sales, resulting in the overall net loss.”

Mr. Dumoulin-White added, “The Company is poised for significant growth in the 2nd half of 2011 as the Company expands its sales and marketing efforts in Canada, the US and internationally with the addition of qualified sales professionals, including the launch of an experienced equine sales team. As well, the Company is preparing for the unveiling of its patented TLC‐2000 Biofeedback Therapeutic Laser in 4Q2011. On the research front, exciting progress is being made in the destruction of cancer cells utilizing Theralase’s patented Photo Dynamic Compounds (PDCs) as well as in bacteria destruction. In order to capitalize on this research, we are considering entering into joint venture arrangements and/or strategic alliances.”

Subsequent to the Company’s year-end, Theralase completed an oversubscribed private placement on January 7, 2011 for gross proceeds of $737,500.

The complete consolidated financial statements and MD&A for twelve months ending December 31, 2010 can be found at www.theralase.com and www.sedar.com.

About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications in the United States, Canada and internationally. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. These applications extend to the care of animals by veterinarians. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

Theralase Technologies Inc.
Roger Dumoulin - White,                                                                                    Greg Bewsh
President & CEO                                                                                                  Director of Investor Relations
416-447-8455 ext. 225                                                                                      416-447-8455 ext. 262
rwhite@theralase.com                                                                                       gbewsh@theralase.com 
www.theralase.com

Monday, May 2, 2011

Theralase Offers Free Cold Laser Treatments at Sporting Life’s 10K Run http://ping.fm/kZLT2

Theralase Offers Free Cold Laser Treatments at Sporting Life’s 10K Run in Support of Children with Cancer

Theralase had a successful day at Sporting Life’s 10K Run in support of children with cancer held Sunday, May 1st. At the finish area runners with aches and pains were offered a free Cold Laser Therapy Treatment. Most of the runners confirmed that they felt much better and appreciated Theralase’s participation in the event. Theralase will be present at most major charitable running events this summer in the Toronto area to offer some pain relief for the participants and have the opportunity to explain Theralase’s patented technology.